secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001558370-22-017407
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q3 net loss $4.56M ($0.38/share); cash $25.7M; CEO promoted; GT-02287 Phase 1 expected mid-2023
--------------------------------------------------------------------------------

- Net loss of $4.56M ($0.38 per share) vs $4.66M ($0.39) in Q3 2021.
- Cash, equivalents, and marketable securities $25.7M, providing runway into Q2 2024.
- R&D expenses $1.96M (down 21% YoY); G&A $2.79M (up 27% YoY).
- Matthias Alder promoted to CEO and appointed to board of directors.
- Lead Parkinson's candidate GT-02287 to commence Phase 1 trial in mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/0001558370-22-017407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837022017407/ganx-20221110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer